# Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert

> **NCT05070728** · PHASE3 · TERMINATED · sponsor: **EyePoint Pharmaceuticals, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Uveitis
- Uveitis, Posterior
- Uveitis, Intermediate

## Interventions

- **DRUG:** Sham Injector
- **DRUG:** FAI Insert

## Key facts

- **NCT ID:** NCT05070728
- **Lead sponsor:** EyePoint Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-13
- **Primary completion:** 2023-04-12
- **Final completion:** 2023-04-12
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** No longer pursuing indication
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05070728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05070728, "Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05070728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*